首页> 外文OA文献 >Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma

【2h】

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma

机译：白消安，美法仑和硼替佐米与高剂量美法仑作为多发性骨髓瘤自体造血干细胞移植的条件治疗方案

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Rodriguez Tulio E.; Hari Parameswaran; Stiff Patrick J.; Smith Scott E.; Sterrenberg Danielle; Vesole David H.;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma [J] . Rodriguez Tulio E., Hari Parameswaran, Stiff Patrick J., Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2016,第8期

机译：白消安，美法仑和硼替佐米与高剂量美法仑作为多发性骨髓瘤自体造血干细胞移植的条件治疗方案
2. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib [J] . Aypar Eda, Izzettin Fikret Vehbi, Aki Sahika Zeynep, Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners . 2018,第4期

机译：自体干细胞移植中的调节方案毒性的比较符合多发性骨髓瘤患者：高剂量母蛋白与高剂量梅酚和硼替佐米
3. High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy [J] . HuangW., LiJ., LiH., Leukemia and lymphoma . 2012,第12期

机译：大剂量美法仑与硼替佐米作为新诊断多发性骨髓瘤患者的自体干细胞移植条件疗法，对基于硼替佐米的诱导治疗表现出至少非常好的部分反应
4. HIGH-DOSE MELPHALAN CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN 65 PATIENTS WITH AL AMYLOIDOSIS: ORGAN PROGRESSION CAN BE DELAYED IN PATIENTS REACHING COMPLETE REMISSION [C] . SO Schonland, J.B Dengler, M Hundemer, International Symposium on Amyloidosis . 2008

机译：在65例Al淀粉样蛋白患者中，具有自体蛋白化疗的高剂量蛋白化疗：器官进展可以延迟达到完全缓解的患者
5. Strategies to Improve Outcomes in Multiple Myeloma: Preclinical Therapeutics Targeting MEK, HDAC and BCL-2 and Optimizing Autologous Hematopoietic Cell Transplantation [D] . Miller, Kevin Charles. 2020

机译：改善多发性骨髓瘤结果的策略：靶向MEK，HDAC和BCL-2的临床前治疗方法以及优化自体造血细胞移植
6. Busulfan Melphalan and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma [O] . Tulio E. Rodriguez, Parameswaran Hari, Patrick J. Stiff, -1

机译：白消安美法仑和硼替佐米与高剂量美法仑作为多发性骨髓瘤自体造血干细胞移植的条件治疗方案
7. Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma [O] . Ja Min Byun, Jayoun Lee, Sang-Jin Shin, 2018

机译：Busulfan Plus Melphalan与高剂量Melphalan作为自体干细胞移植的调理方案，用于新诊断的多发性骨髓瘤

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma

著录项

引文网络

相似文献

相关主题

期刊订阅